Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
12
|
pubmed:dateCreated |
1992-7-30
|
pubmed:abstractText |
The 1-beta-D-arabinofuranosylcytosine (ara-C) conjugates 1-O-alkyl (ether) and 1-S-alkyl (thioether) phospholipids, being analogues of ara-CDP-sn-1,2-O-dipalmitoylglycerol (1), showed significant antitumor activity against L1210 and P388 leukemia in vivo. The more active conjugates include the 1-O-alkyl analogues, ara-CDP-rac-1-O-hexadecyl-2-O-palmitoylglycerol (2) and ara-CDP-rac-1-O-octa-decyl-2-O-palmitoylglycerol (3), and the corresponding 1-S-alkyl analogues, ara-CDP-rac-1-S-hexadecyl-2-O-palmitoyl-1-thioglycerol (4) and ara-CDP-rac-1-S-octadecyl-2-O-palmitoyl-1-thioglycerol (5, Cytoros). The conjugates were formulated by sonication, in which the conjugates existed as discs (size 0.01-0.04 microns). Among the conjugates of the three different phospholipids, the 1-S-alkyl analogues 4 and 5 displayed the strongest antitumor activity against L1210 leukemia in mice, followed by the 1-O-alkyl (2 and 3) and the 1-O-acyl (1) analogues. The 1-S-alkyl analogue 5 was considerably more effective than the 1-O-acyl analogue 1 against myelomonocytic WEHI-3B leukemia in mice. Conjugate 5 (Cytoros) showed a significant therapeutic activity in mice with colon 26 carcinoma, M5076 sarcoma, and C-1300 neuroblastoma. Furthermore, this agent inhibited liver metastases of M5076 sarcoma. Conjugates 3 and 5 also inhibited the metastasis of 3-Lewis lung carcinoma to the lungs of mice. Cytoros (5) and its analogues, with other ether and thioether phospholipids, appear to offer increased therapeutic benefit to mice with tumors.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Dec
|
pubmed:issn |
0024-4201
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
26
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1437-44
|
pubmed:dateRevised |
2003-11-14
|
pubmed:meshHeading |
pubmed-meshheading:1819747-Analysis of Variance,
pubmed-meshheading:1819747-Animals,
pubmed-meshheading:1819747-Colonic Neoplasms,
pubmed-meshheading:1819747-Cytarabine,
pubmed-meshheading:1819747-Female,
pubmed-meshheading:1819747-Leukemia L1210,
pubmed-meshheading:1819747-Male,
pubmed-meshheading:1819747-Mice,
pubmed-meshheading:1819747-Mice, Inbred BALB C,
pubmed-meshheading:1819747-Mice, Inbred C57BL,
pubmed-meshheading:1819747-Mice, Inbred DBA,
pubmed-meshheading:1819747-Molecular Structure,
pubmed-meshheading:1819747-Phospholipid Ethers,
pubmed-meshheading:1819747-Prodrugs,
pubmed-meshheading:1819747-Sarcoma, Experimental,
pubmed-meshheading:1819747-Structure-Activity Relationship
|
pubmed:year |
1991
|
pubmed:articleTitle |
1-beta-D-arabinofuranosylcytosine conjugates of ether and thioether phospholipids. A new class of ara-C prodrug with improved antitumor activity.
|
pubmed:affiliation |
Department of Neurosurgery, Roswell Park Cancer Institute, Buffalo, New York 14263.
|
pubmed:publicationType |
Journal Article
|